Libiguins: a remedy for the treatment of sexual dysfunctions

Project description

Utilising the wisdom of a plant to treat sexual dysfunction

Sexual dysfunction has a serious negative effect on quality of life as well as socioeconomic impacts. The current treatments fail to offer a more natural sex life that does not involve prior planning as a prerequisite for sexual intercourse. A novel drug candidate for the treatment of the common types of sexual dysfunction is DIC2024. DIC2024 utilises a principle from Libiguin, a substance derived from a native plant in Madagascar, to induce long-term effects. The EU-funded LIBSED project is developing a business plan to guide clinical development and commercialisation strategies for DIC2024.

Fields of science

• medical and health sciences › basic medicine › pharmacology and pharmacy › drug discovery
• engineering and technology › electrical engineering, electronic engineering, information engineering › electronic engineering › control systems
• medical and health sciences › clinical medicine › integrative and complementary medicine
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs

Programme(s)

• H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme
• H2020-EU.3. - PRIORITY 'Societal challenges
• H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies

Topic(s)

• EIC-SMEInst-2018-2020 - SME instrument

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-1

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

DICOT AB

Net EU contribution

€ 50 000,00

Address

Dag Hammarskjolds Vag 30
752 37 Uppsala
Sweden

Region

Östra Sverige › Östra Mellansverige › Uppsala län

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links

Non-EU contribution

€ 21 429,00